本帖最后由 老马 于 2013-3-13 13:43 编辑
: S+ f' s/ [1 h& ?
' D5 |' b4 [2 Q" @/ n: _- `5 W# O健择(吉西他滨)+顺铂+阿瓦斯汀) Z8 \- p! X9 D4 i) }; H5 w' l
Gemzar +Cisplatin + Avastin! Y' `7 r1 g5 w- Y. f
http://annonc.oxfordjournals.org/content/21/9/1804.full' p1 x3 c7 C" @4 P+ n: [
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) + o' F7 ~/ E8 e; X* q5 i3 i
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 ^- f, A& B, m W8 Q* z8 ZResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. . H3 N0 k0 j( o3 Z- e
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
- M& A5 @/ i& @& z, q$ Z华为网盘附件:
* }. V3 P* o9 p% @+ ]【华为网盘】ava.JPG
5 t9 W; a, Z$ M, i7 j: u( i |